Novartis AG (VTX:NOVN) has been assigned a CHF 90 price target by investment analysts at Baader Bank in a report issued on Monday. The firm presently has a “buy” rating on the stock.
A number of other research analysts have also weighed in on NOVN. Kepler Capital Markets set a CHF 88 target price on Novartis AG and gave the company a “buy” rating in a report on Tuesday, July 4th. Credit Suisse Group set a CHF 77 target price on Novartis AG and gave the company a “sell” rating in a report on Wednesday, July 5th. Deutsche Bank AG set a CHF 80 target price on Novartis AG and gave the company a “neutral” rating in a report on Friday, July 7th. Berenberg Bank set a CHF 85 target price on Novartis AG and gave the company a “neutral” rating in a report on Friday, July 14th. Finally, Goldman Sachs Group, Inc. (The) set a CHF 80 target price on Novartis AG and gave the company a “neutral” rating in a report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company’s stock. Novartis AG currently has a consensus rating of “Hold” and a consensus price target of CHF 86.10.
Shares of Novartis AG (NOVN) opened at 82.20 on Monday. The firm’s 50-day moving average is CHK 83.26 and its 200-day moving average is CHK 80.47. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 85.40. The firm has a market capitalization of CHK 192.59 billion and a P/E ratio of 30.01.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/01/novartis-ag-novn-pt-set-at-chf-90-by-baader-bank.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.